Key result
Following reports of increased stent thrombosis risk at ESC 2006, overall deployment of drug-eluting stents fell sharply from 83% to 58%, with dramatic reductions in off-label indications.
Population
Patients undergoing coronary intervention in a large regional registry
Comparison
Drug-eluting stent (DES) deployment vs Bare-metal stent deployment
Design
Cohort
Follow-up
June 2006 to December 2008
Authors
Loading...
Safety signals can rapidly curb off-label DES use; leaves open whether this shift improved net outcomes.
Observational
Yes
Absolute Event Rate: 58% vs 83%
Following reports of late stent thrombosis in 2006, real-world use of drug-eluting stents fell dramatically by 2008, especially for off-label indications such as STEMI.
Gualano et al. (2010) conducted an observational in Coronary intervention. Reports of increased risk of very late stent thrombosis at ESC 2006 vs. Pre-ESC 2006 period was evaluated on Overall deployment of drug-eluting stents (DES). Following reports of increased stent thrombosis risk at ESC 2006, overall deployment of drug-eluting stents fell sharply from 83% to 58%, with dramatic reductions in off-label indications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: